Debbie W. Lin
Private Equity Investor at Boehringer Ingelheim (Venture Capital)
Network origin in Debbie W. Lin first degree
Entity | Entity type | Industry | |
---|---|---|---|
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts.
16
| Operating Division | Investment Managers | 16 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Debbie W. Lin via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Biotechnology | Director/Board Member Director/Board Member | |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Biotechnology | Director/Board Member Director/Board Member | |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Abalos Therapeutics GmbH
Abalos Therapeutics GmbH BiotechnologyHealth Technology Abalos Therapeutics GmbH engages in the development of an anti-cancer arenavirus-based drug. It focuses on awakening immune responses against tumors and metastases. The company was founded by Karl Lang and Philipp Lang and is headquartered in Essen, Germany. | Biotechnology | Chief Executive Officer Director/Board Member | |
Cardior Pharmaceuticals GmbH
Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
AgomAb Therapeutics NV
AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
Rinri Therapeutics Ltd.
Rinri Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Rinri Therapeutics Ltd. operates as a biotechnology company developing a novel cell-based therapy to restore hearing. The company was founded in 2018 and is headquartered in Sheffield, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Rgenta Therapeutics, Inc.
Rgenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Rgenta Therapeutics, Inc. manufactures medicines for oncology and neurological disorders. The company was founded by Simon Xi, Travis Wager, and Zhiping Weng and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
HepaRegeniX GmbH
HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany. | Miscellaneous Commercial Services | Director/Board Member | |
University of Hohenheim | College/University | Undergraduate Degree | |
DiogenX SAS
DiogenX SAS BiotechnologyHealth Technology DiogenX SAS engages in the discovery and development of biologics therapeutics options of Diabetic patients. It operates in Diabetes preclinical stage business segment. The company was founded by Benjamin Charles, Patrick Collombat and Jean Pascal Tranié on December 24, 2019 and is headquartered in Marseille, France. | Biotechnology | Director/Board Member | |
Centauri Therapeutics Ltd.
Centauri Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Centauri Therapeutics Ltd. engages in manufacturing processing drugs in pharmaceutical preparations for life threatening diseases. The firm focuses on on the discovery and development of novel molecules targeting life threatening diseases. The company was founded by Mike Westby and Stuart Lawson and is headquartered in Sandwich, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Metabomed Ltd.
Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | Pharmaceuticals: Major | Director/Board Member | |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
ArrePath, Inc.
ArrePath, Inc. Information Technology ServicesTechnology Services ArrePath, Inc. is an anti-infective drug discovery company that focuses on addressing the health challenge of drug-resistant infections. The platform's proof-of-concept has been demonstrated in studies published in Cell by ArrePath's scientific founder, Zemer Gitai, Ph.D., Edwin Grant Conklin Professor of Biology at Princeton University. The company is based in Princeton, NJ, and is funded by the Boehringer Ingelheim Venture Fund, Insight Partners, Innospark Ventures, Viva BioInnovator, Arimed Capital, PTX Capital, and Nor'easter Ventures. The company utilizes a proprietary machine learning-based platform to efficiently identify anti-infective agents with new mechanisms of action at the outset of the discovery process. This is achieved through a deep understanding and analysis of pathogen behavior. The CEO of the company is Lloyd J. Payne. | Information Technology Services | Director/Board Member | |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | Packaged Software | Director/Board Member | |
Bodyport, Inc.
Bodyport, Inc. Packaged SoftwareTechnology Services Bodyport, Inc. manufactures sensor fitted weighing scales. It offers scale that measures weight like others do, but also measures blood pressure, heart rate, heart rate variability, and arterial stiffness through a user's feet. The company was founded by Corey Centen and Sarah Smith and is headquartered in San Francisco, CA. | Packaged Software | Director/Board Member | |
TigaTx, Inc.
TigaTx, Inc. BiotechnologyHealth Technology TigaTx, Inc. is a biotechnology company that focuses on developing first-in-class, engineered IGA as neutrophil engagers to fight cancer. The company is based in Boston, MA. TigaTx is backed by excellent investors and has an accomplished scientific advisory board. It was founded by Jeanette Leusen and the CEO is Anne Altmeyer. | Biotechnology | Director/Board Member | |
Axine Water Technologies, Inc.
Axine Water Technologies, Inc. Chemicals: Major DiversifiedProcess Industries Axine Water Technologies, Inc. provides chemical-free solutions for treating concentrations of toxic organics and ammonia. The firm develops solutions to avoid production bottlenecks, high treatment, disposal costs and water reuse limitations. The company was founded by Colleen Freda Legzdins in 2010 and is headquartered in Vancouver, Canada. | Chemicals: Major Diversified | Chief Executive Officer | |
Brainomix Ltd.
Brainomix Ltd. BiotechnologyHealth Technology Brainomix Ltd. develops imaging biomarkers for neurological and cerebrovascular disorders. It offers e-ASPECTS, medical imaging software that automates a scoring system on brain images from acute ischaemic stroke patients to identify and quantify signs of early stroke damage and assist the physician's decision to treat. The company founded by Michalis Papadakis, Alastair Buchan, Iris Grunwald, Constantin Thiopoulos, and Michael Printzos in 2010 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Director/Board Member | |
High-Tech Gründerfonds Management GmbH
High-Tech Gründerfonds Management GmbH Investment ManagersFinance High-Tech Gründerfonds Management GmbH (HTGF) is a venture capital firm founded in 2005. The firm is headquartered in Bonn, Germany. | Investment Managers | Private Equity Investor | |
University of Bonn | College/University | Doctorate Degree | |
Aignostics GmbH
Aignostics GmbH Packaged SoftwareTechnology Services Aignostics GmbH provides diagnostics services. The company is headquartered in Berlin, Germany. | Packaged Software | Director/Board Member | |
Remiges Ventures Inc.
Remiges Ventures Inc. Investment ManagersFinance Remiges Ventures Inc. (Remiges Ventures) is a venture capital firm founded in 2014 by Taro Inaba. It is headquartered in Cambridge, United States. | Investment Managers | Private Equity Investor | |
Nagoya City University | College/University | Doctorate Degree | |
Actym Therapeutics, Inc.
Actym Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actym Therapeutics, Inc. engages in development of novel immuno-oncology therapies. The company was founded by Christopher D. Thanos and Laura Hix Glickman and is headquartered in Berkeley, CA. | Pharmaceuticals: Major | Director/Board Member | |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Pharmaceuticals: Major | Director/Board Member | |
T-Knife GmbH
T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Biotechnology | Director/Board Member | |
TigaTx BV
TigaTx BV Miscellaneous Commercial ServicesCommercial Services TigaTx BV is a Dutch company that provides research and development in the field of health nutrition. The company is based in Utrecht, the Netherlands. The company was founded in 2020 by Jeanette Leusen. | Miscellaneous Commercial Services | Director/Board Member | |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
Johann Wolfgang Goethe-Universität Frankfurt am Main | College/University | Doctorate Degree | |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Hospital/Nursing Management | Director/Board Member | |
Sentien Biotechnologies, Inc.
Sentien Biotechnologies, Inc. BiotechnologyHealth Technology Sentien Biotechnologies, Inc. develops cell-based therapy for critical care. It provides the Sentinel, a device that actively treats patients during a dialysis dose by supplementing patient blood with MSC-derived secretions. The company was founded by Brian Miller and Biju Parekkadan and is headquartered in Lexington, MA. | Biotechnology | Director/Board Member | |
Tilos Therapeutics, Inc.
Tilos Therapeutics, Inc. BiotechnologyHealth Technology Tilos Therapeutics, Inc. designs and develops biotechnology products such as developing new treatments for cancer, fibrosis and autoimmune disease. It develops antibody therapeutics that target key immunological pathways, with a primary focus on regulatory T cells and regulation of effector cells. The company was founded by Howard L. Weiner in 2016 and is headquartered in Lexington, MA. | Biotechnology | Director/Board Member | |
Abexxa Biologics, Inc.
Abexxa Biologics, Inc. Pharmaceuticals: MajorHealth Technology AbeXXa Biologics, Inc. is engaged in biopharmaceutical services. The company was founded by Jon Weidanz and Debra Weidanz in 2015 and is headquartered in Arlington, TX. | Pharmaceuticals: Major | Director/Board Member | |
Venatorx Pharmaceuticals, Inc.
Venatorx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA. | Miscellaneous Commercial Services | Director/Board Member | |
Topas Therapeutics GmbH
Topas Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Topas Therapeutics GmbH engages in pharmaceutical preparations. The company is headquartered in Hamburg, Germany. | Pharmaceuticals: Major | Chairman | |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Medical Specialties | Director/Board Member | |
Acousia Therapeutics GmbH
Acousia Therapeutics GmbH BiotechnologyHealth Technology Acousia Therapeutics GmbH identifies small molecules for treatment of hearing loss. The firm develops drugs for local application, which will protect hearing function or restore hearing in patients who have lost their hearing ability due to various reasons. It also develops small molecule compounds that trigger regeneration of sensory hair cells and therefore allow casual treatment of sensorineural hearing loss in patients who already lost their hair cells years ago. The company was founded by Hubert Löwenheim and Karl-Heinz Wiesmüller in 2012 and is headquartered in Tübingen, Germany. | Biotechnology | Director/Board Member | |
STAT-Dx Life SL
STAT-Dx Life SL Medical SpecialtiesHealth Technology STAT-Dx Life SL focuses on the development, manufacturing and commercialization of diagnostic solutions for fast and accurate diagnostic results of infectious diseases and critical care. It solution offers DiagCORE Cartridge, for sample and analyzation of cell material, nucleic acid purification, amplification and hybridization process. The company was founded by Jordi Cabrrera Fabra and Rafael Bru Gibert in 2010 and is headquartered in Barcelona, Spain. | Medical Specialties | Director/Board Member | |
T3 Pharmaceuticals AG
T3 Pharmaceuticals AG BiotechnologyHealth Technology T3 Pharmaceuticals AG provides medicines and treatment for cancer patient. The company was founded in May 2015 by Simon J. Ittig, Christoph A. Kasper, Marlise Amstutz and Helmut H. Kessmann and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Rigontec GmbH
Rigontec GmbH Pharmaceuticals: MajorHealth Technology Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany. | Pharmaceuticals: Major | Director/Board Member | |
Kyoto University | College/University | Graduate Degree |
Statistics
International
Germany | 15 |
United States | 13 |
Belgium | 5 |
Switzerland | 4 |
United Kingdom | 4 |
Sectoral
Health Technology | 28 |
Commercial Services | 8 |
Consumer Services | 6 |
Technology Services | 5 |
Finance | 3 |
Operational
Director/Board Member | 47 |
Private Equity Investor | 16 |
Doctorate Degree | 3 |
Corporate Officer/Principal | 2 |
Chairman | 2 |
Most connected contacts
- Stock Market
- Insiders
- Debbie W. Lin
- Company connections